News Paradigm Biopharmaceuticals Limited

Equities

PAR

AU000000PAR5

Market Closed - Australian S.E. Other stock markets 02:10:45 2024-04-19 am EDT			5-day change	1st Jan Change
0.285 ^AUD	0.00%		0.00%	-32.94%

Apr. 19	Paradigm Biopharmaceuticals Submits Documents to FDA for Phase 3 Osteoarthritis Program	MT
Feb. 28	Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Paradigm Biopharmaceuticals Submits Documents to FDA for Phase 3 Osteoarthritis Program	Apr. 18	MT
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Paradigm Biopharma's Injectable Pentosan Polysulfate Sodium Trial Reaches Endpoint	Feb. 12	MT
Paradigm Biopharmaceuticals Secures AU$7 Million R&D Tax Incentive Rebate for Fiscal Year 2023; Shares Rally 9%	Feb. 06	MT
Paradigm Biopharmaceuticals Opens Retail Entitlement Offer	Nov. 06	MT
Paradigm Biopharmaceuticals Raising AU$30 Million for Clinical Trial	23-10-30	MT
Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately	23-10-20	CI
Paradigm Biopharmaceuticals Validates Cartilage Preservation in Knee Osteoarthritis Trial	23-10-18	MT
Paradigm Biopharmaceuticals Confirms Effectivity of Pain Medication in Osteoarthritis Trial	23-10-10	MT
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-25	CI
Paradigm Biopharmaceuticals Validates Efficacy of Anti-Inflammatory Medication in Canine Trial	23-06-02	MT
Australia’s Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up	23-04-11	AQ
Paradigm Biopharmaceuticals Announces Phase 2 Trial in Osteoarthritis Shows Signs of Disease Modification At 6-Month Follow-Up	23-04-11	CI
Paradigm Biopharmaceuticals Limited Announces Injectable PPS Demonstrates Multiple Signals of A DMOAD in PARA_OA_008 Phase 2 Clinical Study	23-04-03	CI
Paradigm Biopharmaceuticals Secures European Ethics Approval for Knee Osteoarthritis Trial	23-03-14	MT
Paradigm Biopharmaceuticals Ltd Receives European Regulatory and Ethics Approval for the Pivotal PARA_OA_002 Global Clinical Trial	23-03-13	CI
Starpharma Appoints CFO	23-03-03	MT
Paradigm Biopharmaceuticals Names Interim CFO	23-03-02	MT
Paradigm Biopharmaceuticals Limited Announces the Change of Chief Financial Officer	23-03-02	CI
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Paradigm Biopharmaceuticals Limited

Equities

PAR

AU000000PAR5

Summary

Filters